Medical therapy in the management of preterm birth

References

• Amon E. Preterm labor. Medicine of the fetus and mothers, E A Reece, J C Hobbins. Lippincott-Raven, Philadelphia 1999; 1529–1579
   Google Scholar
• Cunningham F G, Gant N F, Leveno K J, Gilstrap L C, Hauth J C, Wenstrom K D. Preterm birth 21th ed. International Edition, Obstetrics Williams. Mc Graw-Hill Companies Inc., New YorkUSA 2001; 689–727, Chapter 27
   Google Scholar
• Di Renzo G C, Cabero Roura L, the European Association of Perinatal Medicine Study Group on “Preterm Birth”. Guidelines for the management of spontaneous preterm labor. J Perinat Med 2006; 34: 359–366
   PubMed Web of Science ®Google Scholar
• Robertson P A, et al. Neonatal morbidity according to gestational age and birth weight from five tertiary care centers in the United States, 1983 trough 1986. Am J Obstet Gynecol 1992; 166: 1629–1634
   PubMed Web of Science ®Google Scholar
• World Health Organization, Geneva. ICD-10. Second Edition. International Statistical Classification of Disease and Related Health Problems. 1993; 2, 10th revision
   Google Scholar
• To M S, Nicholaides K H. Cervical length at 23 weeks in triplets: prediction of spontaneous preterm delivery. Ultrasound Obstet Gynecol 2000; 16: 515–518
   PubMed Web of Science ®Google Scholar
• Ross M G, Eden R D. Preterm labor, Available at: http://emedicine.medscape.com/article/260998-overview; 2009
   Google Scholar
• Crowley P. Prophylactic corticosteroids for preterm birth. Cochrane Database Syst Rev 2000, ISSUE 2, DOI: 10.1002/14651858. CD000065
   Google Scholar
• CDC. Prevention of perinatal group B streptococcal disease: revised guidelines from CDC. MMWR 2002; 51: 1–22
   Google Scholar
• Haas D M, Imperiale T F, Kirkpatrick P R, Klein R W, Zollinger T W, Golichowski A M. Tocolytic therapy: a meta-analysis and decision analysis. Obstet Gynecol 2009; 113: 585–594
   PubMed Web of Science ®Google Scholar
• de Heus R, Willem B, Erwich H M, van Geijn H P, Gyselaers W J, Hanssens M, Harmark L, van Holsbeke C D, Duvekot J J, Schobben F FAM, Wolf H, Visser G HA. Adverse drug reactions to tocolytic treatment for preterm labour: prospective cohort study. BMJ 2009; 338: b744, Downloaded from bmj.com on 8 July 2009
   PubMed Web of Science ®Google Scholar
• ACOG Committee Opinion n 291. Use of Progesterone to Reduce Preterm Birth 2003; 102(5)1020–1037
   Google Scholar
• Goldenberg G L. The management of preterm labor. ACOG practice bulletin. Int J Gynecol Obstet 2002; 100: 5–Part 1
   Google Scholar
• King J, Flenady V, Cole S, Thornton S. Cyclo-oxygenase (COX) inhibitors for treating preterm labour. Cochrane Database Syst Rev 2005, Issue 2
   Web of Science ®Google Scholar
• Gazzetta Ufficiale della Repubblica Italiana. Modifica degli stampati e del regime di fornitura di specialità medicinali contenenti ritodrina e isoxisuprina. Serie Generale n, 166 del 19/7/2003
   Google Scholar
• Royal College of Obstetrician and Gynaecologists. Tocolytic drug for women in preterm labour. 2002, Clinical Guideline No.1
   Google Scholar
• Inoue Y, Yoshizato T, Kawarabayashi T. Investigation of b2-adrenoceptor subtype selectivity and organ specificity for bedoradrine (KUR-1246), a novel tocolytic β-adrenergic receptor stimulant. J Obstet Gynaecol Res 2009; 35: 405–413
   PubMed Web of Science ®Google Scholar
• Neri M, Monari F, Valensise H, Vasapollo B, Facchinetti F, Volpe A. Computerized evaluation of fetal heart rate during tocolytic treatment: comparison between Atosiban and Ritodrine. Am J Perinatol 2008; 26(4)259–263
   PubMed Web of Science ®Google Scholar
• Coomarasamy A. Progesterone for the prevention of the preterm birth: a critical evaluation of evidence. Eur J Obstet Gynecol Reprod Biol 2006; 129: 111–118
   PubMed Web of Science ®Google Scholar
• Da Fonseca E B, Bttar R E, Carvalho M H, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003; 188: 419–424
   PubMed Web of Science ®Google Scholar
• Meis P J, et al. Prevention of recurrent preterm delivery by 17 α hydroxyprogesterone caproate. N Eng J Med 2003; 348: 2379–2385
   PubMed Web of Science ®Google Scholar
• DeFranco E A, O'Brien J M, Adair C D, et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007; 30: 697–705
   PubMed Web of Science ®Google Scholar
• De Fonseca E B, Ebru C, Parra M, Singh M, Nicolaides K H. Progesterone and the risk of preterm birth among women with short cervix. N Eng J Med 2007; 357: 462–469
   PubMed Web of Science ®Google Scholar
• Romero R, Espinoza J, Kusanovic J, Gotsch F, Hassan S, Erez O, Chaiworapongsa T, Mazor M. The preterm parturition syndrome. BJOG 2006; 113: 17–42
   PubMed Web of Science ®Google Scholar
• Borna S. Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. The Royal Aus and NZCOG 2008; 48: 58–63
   Google Scholar
• Thornton J G. Maintenance tocolysis. BJOG March 2005; 112: 118–121
   PubMed Web of Science ®Google Scholar
• Agenzia Italiana del Farmaco. Tocolitici: farmaci davvero necessari?. Bollettino di Informazione sui Farmaci 2007; XIV, N. 5
   Google Scholar